If IPIX was doing the work the payment would be ex
Post# of 72440
(Total Views: 346)
Posted On: 07/22/2019 10:41:39 AM
If IPIX was doing the work the payment would be exceptionally more.
Innovation Pharmaceuticals Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).
So the work is on them imo. And thinking they like what they see so far. This is a large market and we'll see our chunk imo.
So it does help relieve a bit of pressure. And the fact that we have our validation, well, I'd say that's the best start of all for n otc.
Innovation Pharmaceuticals Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Alfasigma S.p.A., a global pharmaceutical company (“Alfasigma”), granting Alfasigma the worldwide right to develop, manufacture and commercialize locally-administered Brilacidin for the treatment of ulcerative proctitis/ulcerative proctosigmoiditis (UP/UPS).
So the work is on them imo. And thinking they like what they see so far. This is a large market and we'll see our chunk imo.
So it does help relieve a bit of pressure. And the fact that we have our validation, well, I'd say that's the best start of all for n otc.
(5)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼